Iteos Therapeutics Inc (ITOS)
Sector • Healthcare Industry • Biotechnology & Pharmaceuticals |
Industry • Biotechnology & Pharmaceuticals |
Sector • Healthcare |
Iteos Therapeutics Inc declared top-line has dropped by -77.587 %, amid the fiscal time-frame ending December 31 2022
company announced fourth quarter of 2022 operating profit of $17.383 millions
Published Mar 16 2023
CSIMarket Team / CSIMarket.com
For the fourth quarter of 2022 ITOS income fell sharply by -87.3 % of $0.54 per share compare to $4.26 a year ago and earnings per share truly advanced by 1703.04 % from $0.03 per share from the preceding reporting period.
Revenues dropped sharply by -77.587 % to $53.91 millions from $240.50 millions in the comparable reporting period a year ago and sequentially Revenue doubled by 176.62 % from $19.49 millions.
Net earnings of $20.453 millions in the fourth quarter of 2022 fell by -88.94 % from $184.872 millions in the corresponding period a year before. Looking further into fourth quarter of 2022 Iteos Therapeutics Inc 's profitability, operating margin mitigated to 32.25%, and net margin shrank to 37.94%.
Operating earnings, fell -91.86% to $17.383 millions, squeezing Iteos Therapeutics Inc 's operating margin to 32.25%, from 88.78% in the fourth quarter of 2021. Looking further into Iteos Therapeutics Inc s' results for the fiscal 12 Months 2022, ITOS declared Revenues of $267.63 millions and net earnings of $96.65 millions.
Biotechnology & Pharmaceuticals company voiced also, that Income per share faded by -54.93 % to $2.56 per share from $5.68 in the preceding fiscal 12 Months , and contributedRevenues fell by -22.38 % from $344.78 millions a year ago.
Iteos Therapeutics Inc is expected to report next financial recent numbers on May 11, 2023.
Revenues dropped sharply by -77.587 % to $53.91 millions from $240.50 millions in the comparable reporting period a year ago and sequentially Revenue doubled by 176.62 % from $19.49 millions.
Net earnings of $20.453 millions in the fourth quarter of 2022 fell by -88.94 % from $184.872 millions in the corresponding period a year before. Looking further into fourth quarter of 2022 Iteos Therapeutics Inc 's profitability, operating margin mitigated to 32.25%, and net margin shrank to 37.94%.
Operating earnings, fell -91.86% to $17.383 millions, squeezing Iteos Therapeutics Inc 's operating margin to 32.25%, from 88.78% in the fourth quarter of 2021. Looking further into Iteos Therapeutics Inc s' results for the fiscal 12 Months 2022, ITOS declared Revenues of $267.63 millions and net earnings of $96.65 millions.
Biotechnology & Pharmaceuticals company voiced also, that Income per share faded by -54.93 % to $2.56 per share from $5.68 in the preceding fiscal 12 Months , and contributedRevenues fell by -22.38 % from $344.78 millions a year ago.
Iteos Therapeutics Inc is expected to report next financial recent numbers on May 11, 2023.